Astrazeneca Pharma India Ltd

Astrazeneca Phar Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astrazeneca Pharma India Ltd

₹ 8,570 -0.33%
08 Jun 11:13 a.m.
astrazenecaindia.com BSE: 506820 NSE: ASTRAZEN
About

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Key Points

Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]

Website BSE NSE
  • Market Cap ₹ 21,425 Cr.
  • Current Price ₹ 8,570
  • High / Low ₹ 10,691 / 7,552
  • Stock P/E 112
  • Book Value ₹ 349
  • Dividend Yield 0.37 %
  • ROCE 29.3 %
  • ROE 23.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 51.4%

Cons

  • Stock is trading at 24.5 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Midsmallcap400 Momentum Quality 100

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
285 295 311 306 383 388 408 440 480 526 559 612 579
225 228 258 291 334 349 355 363 394 445 484 567 518
Operating Profit 60 67 53 15 49 38 53 77 86 81 75 45 61
OPM % 21% 23% 17% 5% 13% 10% 13% 17% 18% 15% 13% 7% 11%
-32 8 25 10 9 -49 8 -26 10 11 1 7 5
Interest 0 0 0 1 -0 0 0 0 1 1 1 1 2
Depreciation 4 4 4 4 4 4 9 9 18 17 3 4 6
Profit before tax 23 71 73 20 54 -15 51 42 78 75 73 47 58
Tax % 26% 25% 29% 23% 27% -22% 25% 27% 26% 25% 26% 30% 23%
17 54 52 16 39 -12 38 31 58 56 54 33 45
EPS in Rs 6.91 21.54 20.95 6.32 15.79 -4.72 15.37 12.34 23.30 22.33 21.69 13.04 17.95
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
517 564 544 571 728 832 814 806 1,003 1,296 1,716 2,276
528 547 506 525 657 711 678 719 838 1,111 1,462 2,014
Operating Profit -11 16 37 46 71 121 135 86 165 184 254 262
OPM % -2% 3% 7% 8% 10% 15% 17% 11% 16% 14% 15% 12%
6 7 14 12 16 13 13 15 -14 51 -56 23
Interest 0 0 0 0 0 1 1 1 1 1 1 4
Depreciation 15 17 16 15 15 19 20 17 16 15 40 29
Profit before tax -21 6 36 44 73 114 127 83 134 220 156 252
Tax % 0% 9% 44% 41% 25% 37% 27% 26% 26% 26% 26% 26%
-21 5 20 26 54 72 93 62 99 162 116 188
EPS in Rs -8.34 2.10 8.02 10.36 21.78 28.88 37.32 24.64 39.72 64.60 46.30 75.01
Dividend Payout % 0% 0% 0% 0% 0% 3% 5% 41% 40% 37% 69% 48%
Compounded Sales Growth
10 Years: 15%
5 Years: 23%
3 Years: 31%
TTM: 33%
Compounded Profit Growth
10 Years: 43%
5 Years: 16%
3 Years: 15%
TTM: 9%
Stock Price CAGR
10 Years: 23%
5 Years: 18%
3 Years: 35%
1 Year: -12%
Return on Equity
10 Years: 21%
5 Years: 22%
3 Years: 23%
Last Year: 23%

Balance Sheet

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 5 5 5 5 5 5 5 5 5 5 5 5
Reserves 146 151 218 242 296 359 451 506 584 707 765 868
0 0 0 0 0 12 12 9 7 5 36 111
261 247 193 214 261 330 306 337 389 362 712 1,006
Total Liabilities 412 403 415 461 562 706 775 857 985 1,078 1,518 1,989
101 97 87 75 75 72 81 74 69 67 64 117
CWIP 12 6 5 4 7 24 4 2 1 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0
298 299 324 382 480 611 690 780 915 1,011 1,454 1,872
Total Assets 412 403 415 461 562 706 775 857 985 1,078 1,518 1,989

Cash Flows

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-46 57 38 9 55 87 105 101 58 28 65 -15
-19 -4 0 -9 4 -171 173 5 18 22 31 19
0 -1 0 0 0 -6 -9 -9 -24 -44 -66 -92
Net Cash Flow -64 53 38 -1 59 -90 269 96 52 5 31 -88
Free Cash Flow -69 48 33 3 37 74 99 94 53 18 64 -18
CFO/OP 393% 365% 133% 28% 126% 100% 101% 146% 60% 46% 51% 26%

Ratios

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 30 54 29 35 40 37 38 39 39 43 39 34
Inventory Days 157 141 121 229 186 197 198 164 193 140 208 272
Days Payable 203 174 184 257 266 251 221 223 231 121 173 207
Cash Conversion Cycle -16 21 -34 7 -39 -17 15 -20 1 62 74 99
Working Capital Days -15 -28 -36 -8 -14 -16 -17 -34 -18 20 22 50
ROCE % -13% 4% 15% 19% 27% 34% 30% 16% 31% 31% 33% 29%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Employees
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Shareholders
Count
New Medicine and Indication Approvals
Count
Indian Pharmaceutical Market (IPM) Ranking
Rank
AI-Powered Lung Cancer Scans (Cumulative)
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.68% 2.69% 2.66% 2.73% 2.79% 2.90% 2.92% 2.89% 3.03% 2.74% 2.71% 2.78%
1.91% 2.42% 2.76% 3.77% 4.99% 5.08% 5.21% 4.65% 4.55% 5.26% 5.55% 5.79%
20.40% 19.89% 19.57% 18.50% 17.21% 17.02% 16.85% 17.45% 17.41% 17.00% 16.73% 16.42%
No. of Shareholders 38,94632,38029,03229,41827,16927,61527,32232,46634,37832,91431,55129,007

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls